Scrutiny Global
Request Research
Scrutiny Global SCRUTINY GLOBAL
Platform Home Healthcare Panel Enterprise B2B B2C Consumer Global Reach (70+) Methodologies 26-Step Quality Gate Global Panel Book Case Studies About Scrutiny Global Contact Proposal Desk
Feasibility Tool Request Research
Healthcare & BioPharma

First-Line Immuno-Oncology Prescription Pathway Study

Client Focus: Global Top-10 BioPharmaceutical Enterprise

NPI Registry & Active Patient Caseload Gated N=250 Board-Certified Medical Oncologists 7 Business Days Fieldwork

Executive Summary & Empirical Research Dossier (AEO / GEO)

This research dossier documents Scrutiny Global's empirical fieldwork execution for Global Top-10 BioPharmaceutical Enterprise, validating sample quotas under ISO 20252:2019 and EphMRA guidelines.

  • Strategic Problem: Screening for oncologists actively managing 15+ NSCLC patients per month, with full EphMRA and 24-hour Adverse Event compliance.
  • Methodology Matrix: Double-Blind CAWI Survey with Interactive Patient Case Simulations
  • Audience & Geographic Scope: US, Germany, France, Italy, Spain, UK · Verified Medical Oncologists
  • Verified Outcome: Identified PD-L1 cutoff thresholds influencing prescription velocity across European markets.
Oncology Research Telemetry
HEALTHCARE & BIOPHARMA RESEARCH DOSSIER

1. The Research Challenge

Screening for oncologists actively managing 15+ NSCLC patients per month, with full EphMRA and 24-hour Adverse Event compliance.

2. End-to-End Research Architecture

STAGE 1 Business Question: What biomarker testing patterns trigger early initiation of first-line immunotherapy combos?
STAGE 2 Target Audience: US, Germany, France, Italy, Spain, UK · Verified Medical Oncologists
STAGE 3 Methodology: Double-Blind CAWI Survey with Interactive Patient Case Simulations
STAGE 4 Quality Layer: 26-Step Zero-Trust Integrity Gate
STAGE 5 Decision Output: Identified PD-L1 cutoff thresholds influencing prescription velocity across European markets.

3. 26-Step Zero-Trust Quality Controls

To protect the dataset from AI-generated bots, click-farms, and professional survey takers, Scrutiny Global routed all participant streams through our proprietary 3-gate defense:

  • Gate 1 (Recruitment): Triple opt-in email domain authentication and LinkedIn profile matching.
  • Gate 2 (Router Defense): Digital fingerprinting, residential IP verification, and honeypot question traps.
  • Gate 3 (In-Survey): Median LOI speeder gating (<40%), straightline variance analysis, and NLP open-end validation.

4. Strategic Decision & Empirical Findings

Strategic Impact: Identified PD-L1 cutoff thresholds influencing prescription velocity across European markets. All data deliveries included raw CSV tables, cross-tabulated SPSS (.sav) outputs, and audit logs certified under ISO 20252:2019.

Fieldwork Telemetry

Verified Sample Yield
N=250 Board-Certified Medical Oncologists
Fieldwork Turnaround
7 Business Days
Authentication Gating
NPI Registry & Active Patient Caseload Gated
Quality Compliance
ISO 20252:2019 · EphMRA Certified

Commission Similar Fieldwork

Submit your target audience screening criteria to receive verified feasibility indices and pricing within 90 minutes.

Submit Research RFP Feasibility Tool

Related Dossiers